SecBot SecBot
8-K ·Filed May 18, 2026

BSX

BOSTON SCIENTIFIC CORP
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago SEC0000885725-26-000041
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

This is a significant strategic entry into the TAVR market, a high-growth structural heart segment where BSX currently has no product. The SIEGEL valve's differentiated design (nickel-free, smaller sheath) and early clinical data position it as a potential competitor to Edwards and Medtronic. Watch for STAR trial enrollment updates and FDA milestone announcements as catalysts for the call option exercise. The $3.0 billion option price implies a ~$4.5 billion total enterprise value for the TAVR asset, which is reasonable given the market opportunity.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$55.89
T+0 close · May 18, 2026 · via day close
Latest settled
−8.04%
T+60 · $51.40
Vs SPY
−12.62%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $55.89entry
  2. T+1 · 6mo ago +1.66%α +2.31% · $56.82
  3. T+5 · 6mo ago +3.10%α +1.48% · $57.62
  4. T+20 · 5mo ago −16.33%α −18.52% · $46.76
  5. T+60 · 3mo ago −8.04%α −12.62% · $51.40

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Boston Scientific invested $1.5 billion for a 33.75% equity stake in MiRus LLC, a privately-held developer of the SIEGEL TAVR system, and obtained an exclusive option to acquire the TAVR business for an additional $3.0 billion upon achievement of clinical and regulatory milestones. The investment provides BSX with a differentiated, nickel-free balloon-expandable TAVR valve currently in a pivotal trial, though the device remains investigational and not yet approved for commercial sale.

Key Facts

  • BSX acquired 33.75% of MiRus for $1.5 billion cash (plus a prior $100 million payment) on May 15, 2026.
  • BSX holds an exclusive call option to acquire the TAVR-Structural Heart NewCo for an additional $3.0 billion in cash upon milestone achievement.
  • The SIEGEL TAVR valve is the first nickel-free, balloon-expandable TAVR system, delivered through an 8 French sheath (50% smaller than current sheaths).
  • MiRus recently initiated the STAR pivotal trial (up to 1,025 patients) for FDA PMA approval.
  • The investment is expected to be immaterial to BSX's adjusted EPS in 2026.
  • If BSX does not exercise the call option, its equity stake will be forfeited or reduced by ~75%.

Financial Impact

$1.5 billion cash investment for 33.75% stake, with a potential additional $3.0 billion for full ownership of the TAVR business; immaterial to 2026 adjusted EPS.

casheps

Risk Factors

  • The SIEGEL valve is investigational and not yet approved in any country; pivotal trial failure or regulatory delays could impair the investment.
  • If BSX does not exercise the call option, the $1.5 billion equity stake is largely forfeited (~75% reduction), representing a substantial loss.
  • Integration risk and competition from established TAVR players (Edwards, Medtronic) could limit commercial uptake even if approved.
  • The $3.0 billion option payment plus potential sales-based milestones represent significant future cash outflows.

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
88% bullish (41 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000885725-26-000041
Exhibit: exhibit991-pressrelease_fi.htm0000885725-26-000041
Document: 0000885725-26-000041-index-headers.html0000885725-26-000041
Document: 0000885725-26-000041-index.html0000885725-26-000041
Document: 0000885725-26-000041.txt0000885725-26-000041

Track record

22 reports on BSX

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +9.24% at T+20 after the Aug 26, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Oct 28, 202619d ago 8-K Bearish 6/10 No price data
  2. Oct 28, 202619d ago Press Release Bearish 5/10 Entry $42.43 Now $43.69 −2.97% settles Nov 25
  3. Oct 23, 202624d ago Institutional Cluster Bearish 4/10 Entry $45.69 Now $43.69 +4.38% settles Nov 20
  4. Oct 7, 20265w ago 8-K Mixed 6/10 Entry $41.58 to $45.82 Now $43.69 +5.07% ▲ +10.20% +11.54% vs SPY
  5. Sep 23, 20267w ago 8-K Bearish 5/10 Entry $44.62 to $44.51 Now $43.69 +2.08% ▲ +0.25% +0.93% vs SPY
  6. Aug 31, 202611w ago Court Ruling Neutral 2/10 Entry $48.08 to $43.65 Now $43.69 −9.13% ▼ −9.21% −9.57% vs SPY
  7. Aug 26, 202611w ago 8-K Bearish 6/10 Entry $48.17 to $43.72 Now $43.69 +9.30% ▲ +9.24% +10.44% vs SPY
  8. Aug 22, 202612w ago Institutional Cluster Mixed 6/10 Entry $49.01 to $44.92 Now $43.69 −10.85% ▼ −8.35% −9.66% vs SPY
  9. Aug 7, 202614w ago Insider Cluster Mixed 6/10 Entry $50.46 to $44.98 Now $43.69 −13.42% ▼ −10.86% −9.95% vs SPY
  10. Aug 7, 202614w ago Insider Cluster Mixed 5/10 Entry $50.46 to $44.98 Now $43.69 −13.42% ▼ −10.86% −9.95% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens Tue (17h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026